文献速递青光眼

高选择性ROCK抑制剂ITRI-E-212局部给药降眼压且结膜充血发生率低

A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究探讨新型ROCK抑制剂ITRI-E-212的降眼压效果。在正常眼压和高眼压兔模型中,ITRI-E-212平均降眼压幅度分别为24.9%和28.6%,1%制剂每日一次点眼后降眼压作用持续至少6小时,仅观察到短暂轻度结膜充血。

要点

  • ITRI-E-212在正常眼压和高眼压兔模型中平均降眼压24.9%和28.6%。
  • 1% ITRI-E-212每日一次点眼,降眼压作用持续至少6小时。
  • 仅见短暂轻度结膜充血,眼表耐受性良好。

核心结论

  • ITRI-E-212是一种新型高选择性ROCK2抑制剂,在动物模型中可降低眼压。
  • ITRI-E-212具有较好的药代动力学和眼部耐受性,仅引起轻微结膜充血。

研究设计与样本

  • 从200多种氨基异喹啉结构中筛选出ITRI-E-212,因其在滴眼液中溶解度和载药百分比合适。
  • 体外采用ADP-Glo激酶 assay 评估激酶抑制活性,并用KINOMEscan方法分析激酶抑制剂选择性。
  • 在正常眼压和高眼压兔模型中研究降眼压效果和耐受性,并在活体房水中进行药代动力学研究,同时评估充血。

主要发现

  • ITRI-E-212对ROCK2具有高体外抑制活性,并对AGC激酶具有高选择性。
  • ITRI-E-212在正常眼压和高眼压模型中的平均降眼压效果分别为24.9%和28.6%。
  • 1% ITRI-E-212每日一次给药后,眼压显著降低并持续至少6小时。
  • 仅观察到短暂、轻度充血。
  • 给药后1小时从房水提取的化合物达到78.4%的ROCK2激酶抑制,并持续4小时。

临床怎么用

  • ITRI-E-212有望开发为新型抗青光眼药物,局部给药可降眼压且结膜充血发生率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to investigate the IOP-lowering effects of the ITRI-E-212, a new Rho-associated protein kinase (ROCK) inhibitor. ITRI-E-212 improved fluid outflow through the trabecular meshwork and reduced IOP with transient and mild conjunctival hyperemia. ITRI-E-212 can potentially be developed into new antiglaucoma agents. METHODS: ITRI-E-212 was selected from more than 200 amino-isoquinoline structures because of its adequate solubility and drug-loading percentage in eye drops. ITRI-E-212 has less than 50% inhibitory concentration (IC50) against ROCK2. The in vitro kinase inhibition was evaluated using the ADP-Glo kinase assay. A comprehensive analysis of the kinase inhibitor selectivity of ITRI-E-212 was performed using the KINOMEscan methodology. The IOP-lowering effect and tolerability of ITRI-E-212 were investigated in normotensive and ocular hypertensive rabbits. The pharmacokinetics study was performed in vivo in the aqueous humor (AH), and hyperemia was assessed. RESULTS: ITRI-E-212 showed high in vitro inhibitory activity against ROCK2 and high specificity against AGC kinases. The mean IOP-lowering effect of ITRI-E-212 in normotensive and ocular hypertensive models was 24.9% and 28.6%, respectively; 1% ITRI-E-212 produced notable reductions in IOP that were sustained for at least 6 hours after each dose once per day. Only transient, mild hyperemia was observed. The compound extracted from the AH reached 78.4% ROCK2 kinase inhibition at 1 hour after dose administration and was sustained for 4 hours. CONCLUSIONS: ITRI-E-212 is a novel and highly specific ROCK2 inhibitor with the ability to lower IOP in animal models. It has favorable pharmacokinetic and ocular tolerability profiles with only minimal conjunctival hyperemia.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Hsu CR, Chen YH, Liu CP, et al. A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia. Invest Ophthalmol Vis Sci. 2019. PMID: 30735565. doi:10.1167/iovs.18-25252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。